Large Outflow of Money Witnessed in NxStage Medical

NxStage Medical (NXTM): The stock had negative money flow to the tune of ($0.96 million) on Wednesday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $0.8 million, whereas, the outflow of money on downticks was $1.76 million and the ratio between the two was 0.46. The block trade had a negative net money flow of ($0.86 million). The total block trade value undertaken on upticks was $0.25 million. On the other hand, downticks amounted to $1.1 million of the traded value, which shows distribution in the stock by traders. The ratio between uptick and downtick was 0.22. NxStage Medical (NXTM) closed with marginal gains of 27 cents to end the day at $24.68, an increase of 1.11% over the previous days close. The stock recorded -0.4% for the week.

NxStage

Nxstage Medical, Inc. has dropped 0.65% in the last five trading days, however, the shares have posted positive gains of 5.62% in the last 4 weeks. Nxstage Medical, Inc. is up 15.46% in the last 3-month period. Year-to-Date the stock performance stands at 12.46%.

NxStage Medical (NXTM) : Zacks Investment Research ranks NxStage Medical (NXTM) as 3, which is a Hold recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 8 research analysts is 1.5, which indicates as a Strong Buy.

NxStage Medical (NASDAQ:NXTM): The stock opened at $24.43 and touched an intraday high of $24.8 on Wednesday. During the day, the stock corrected to an intraday low of $24.37, however, the bulls stepped in and pushed the price higher to close in the green at $24.64 with a gain of 0.94% for the day. The total traded volume for the day was 476,979. The stock had closed at $24.41 in the previous trading session.

NxStage Medical, Inc. is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product, the System One, is a small, portable, easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One, In-Center and Services.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.